NDAORALTABLET
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
Iron Chelating Activity
Pharmacologic Class:
Iron Chelator
Clinical Trials (2)
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
Started Jan 2012
0Acute Kidney Injury
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
Started Jun 2010
60 enrolled
Contrast-Induced Acute Kidney Injury
Loss of Exclusivity
LOE Date
Oct 25, 2038
153 months away
Patent Expiry
Oct 25, 2038
Exclusivity Expiry
Apr 30, 2028